Omeros Corporation (OMER) - Total Liabilities
Based on the latest financial reports, Omeros Corporation (OMER) has total liabilities worth $349.51 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Omeros Corporation - Total Liabilities Trend (2007–2025)
This chart illustrates how Omeros Corporation's total liabilities have evolved over time, based on quarterly financial data. See how liquid is Omeros Corporation's working capital to evaluate short-term liquidity relative to the company's equity base.
Omeros Corporation Competitors by Total Liabilities
The table below lists competitors of Omeros Corporation ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Dakota Gold Corp.
NYSE MKT:DC
|
USA | $3.34 Million |
|
Indika Energy Tbk
JK:INDY
|
Indonesia | Rp1.57 Billion |
|
India Glycols Limited
NSE:INDIAGLYCO
|
India | Rs35.90 Billion |
|
Laan & Spar Bank AS
CO:LASP
|
Denmark | Dkr37.37 Billion |
|
Logistea AB Series B
ST:LOGI-B
|
Sweden | Skr9.63 Billion |
|
Elec-Tech International Co Ltd
SHE:002005
|
China | CN¥770.56 Million |
|
Regional Container Lines Public Company Limited
BK:RCL-R
|
Thailand | ฿23.02 Billion |
|
RaySearch Laboratories AB (publ)
ST:RAY-B
|
Sweden | Skr984.80 Million |
Liability Composition Analysis (2007–2025)
This chart breaks down Omeros Corporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Omeros Corporation stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.03 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -5.52 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.22 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Omeros Corporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Omeros Corporation (2007–2025)
The table below shows the annual total liabilities of Omeros Corporation from 2007 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $446.86 Million | -2.79% |
| 2024-12-31 | $459.69 Million | +14.00% |
| 2023-12-31 | $403.25 Million | -20.19% |
| 2022-12-31 | $505.29 Million | +27.76% |
| 2021-12-31 | $395.49 Million | +31.05% |
| 2020-12-31 | $301.79 Million | +22.69% |
| 2019-12-31 | $245.99 Million | -5929.15% |
| 2018-12-31 | $-4.22 Million | -103.54% |
| 2017-12-31 | $119.14 Million | +13.77% |
| 2016-12-31 | $104.72 Million | +39.21% |
| 2015-12-31 | $75.23 Million | +39.98% |
| 2014-12-31 | $53.74 Million | +53.91% |
| 2013-12-31 | $34.92 Million | -85.52% |
| 2012-12-31 | $241.15 Million | +641.19% |
| 2011-12-31 | $32.54 Million | +28.94% |
| 2010-12-31 | $25.23 Million | +33.39% |
| 2009-12-31 | $18.92 Million | -83.24% |
| 2008-12-31 | $112.85 Million | +16.21% |
| 2007-12-31 | $97.10 Million | -- |
About Omeros Corporation
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinic… Read more